EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)VergleichsstudieOpen Access · CC BY 4.0

Bioequivalence and the food effect of macitentan/tadalafil 10/20 fixed‐dose combination tablets versus the use of single‐component tablets in healthy subjects

Jennifer Lynn Ford iD, Ahad Sabet iD, Jaya Natarajan iD, Hans Stieltjes iD, Daniel L Chao iD, Navin Goyal iD, Denes Csonka iD

Pharmacology Research & Perspectives · 2024-06 · 12 (3)

DOI: 10.1002/prp2.1202 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Pharmacology Research & Perspectives, online erschienen am 19.05.2024. Verfasst von Jennifer Lynn Ford und 6 weiteren Autor:innen. Beteiligte Einrichtung: Janssen Research & Development, Spring House, Pennsylvania, USA. Hauptthemen laut MEDLINE: Therapeutic Equivalency, Cross-Over Studies, Pyrimidines, Food-Drug Interactions. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The primary aim was to demonstrate bioequivalence between the 10/20 mg fixed‐dose combination (FDC) of macitentan/tadalafil in a single tablet and the free combination of both drugs, and to evaluate the food effect on the 10/20 mg FDC in healthy participants. In this single‐center, randomized, open‐label, 3‐way crossover, single‐dose Phase 1 study in healthy adult participants, macitentan/tadalafil was administered as a 10/20 mg FDC formulation and compared with the free combination of macitentan and tadalafil. The food effect on the FDC was also evaluated. Pharmacokinetic sampling (216 h) was conducted. The 90% confidence intervals (CIs) for the geometric mean ratios of maximum observed plasma analyte concentration ( C max ) and area under the plasma analyte concentration–time curves (AUCs) for Treatment A (FDC, fasted) versus C (free combination, fasted) were within bioequivalence limits demonstrating that the FDC formulation can be considered bioequivalent to the free combination. The 90% CIs for the geometric mean ratios of C max and AUC for Treatment B (FDC, fed) versus A (FDC, fasted) were contained within bioequivalence limits demonstrating that there was no food effect. The administration of the 10/20 mg FDC was generally safe and well tolerated in healthy participants. This study demonstrated bioequivalence between the FDC of macitentan/tadalafil (10/20 mg) in a single tablet and the free combination of both drugs in healthy participants, and that the FDC can be taken without regard to food, similarly to the individual components. The FDC was generally safe and well tolerated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Therapeutic EquivalencyCross-Over StudiesPyrimidinesFood-Drug InteractionsTabletsTadalafilDrug CombinationsHealthy VolunteersSulfonamidesArea Under CurveHumansMaleAdultYoung AdultFemaleMiddle AgedAdministration, OralFastingAdolescent

Stichwörter der Autor:innen

bioequivalencefixed‐dose combinationfood effectmacitentanpulmonary arterial hypertensiontadalafil

Substanzen

PyrimidinesTabletsTadalafilDrug CombinationsSulfonamidesmacitentan

Autor:innen und Institutionen

  • Janssen Research & Development, Spring House, Pennsylvania, USA.
  • ICON, Salt Lake City, Utah, USA.
  • Janssen Research & Development, Raritan, New Jersey, USA.
  • Janssen Research & Development, Beerse, Belgium.
  • Actelion Pharmaceuticals, A Janssen Pharmaceutical Company of Johnson & Johnson, Allschwil, Switzerland.

ORCID-Profile: Jennifer Lynn Ford, Ahad Sabet, Jaya Natarajan, Hans Stieltjes, Daniel L Chao, Navin Goyal, Denes Csonka

Förderung

  • Janssen Research and Development

Zitieren

APA

Ford, J. L., Sabet, A., Natarajan, J., Stieltjes, H., Chao, D. L., Goyal, N., & Csonka, D. (2024). Bioequivalence and the food effect of macitentan/tadalafil 10/20 fixed‐dose combination tablets versus the use of single‐component tablets in healthy subjects. Pharmacology Research & Perspectives, 12(3). https://doi.org/10.1002/prp2.1202

Vancouver

Ford JL, Sabet A, Natarajan J, Stieltjes H, Chao DL, Goyal N, et al. Bioequivalence and the food effect of macitentan/tadalafil 10/20 fixed‐dose combination tablets versus the use of single‐component tablets in healthy subjects. Pharmacology Research & Perspectives. 2024;12(3). doi:10.1002/prp2.1202

BibTeX
@article{Ford2024,
  author = {Ford, Jennifer Lynn and Sabet, Ahad and Natarajan, Jaya and Stieltjes, Hans and Chao, Daniel L and Goyal, Navin and Csonka, Denes},
  title = {Bioequivalence and the food effect of macitentan/tadalafil 10/20 fixed‐dose combination tablets versus the use of single‐component tablets in healthy subjects},
  journal = {Pharmacology Research & Perspectives},
  year = {2024},
  volume = {12},
  number = {3},
  doi = {10.1002/prp2.1202}
}
Kostenlos starten →